
For the quarter ended Sept. 30, revenue fell 22 per cent at Radnostix, Inc. OTCMKTSINIS, the radioisotope manufacturer reported on Monday. Its net loss widened to US$842,242 from US$203,601 in the comparable quarter.
Revenue was US$2.57 million against US$3.28 million a year earlier, according to the company's Nov. 16 results release. The comparison covers the third quarter, rather than the nine-month period, for which revenue declined 25 per cent.
Cash and cash equivalents stood at US$0.71 million on Sept. 30. A separate US$1.53 million of restricted cash supported Nuclear Regulatory Commission financial assurance. In October, Radnostix arranged a US$1 million revolving credit facility to provide working capital.
Shares traded lower at US$0.038 in the U.S. OTC market at 12:43 p.m. EST on Nov. 16, according to OTCMKTSINIS.
Radnostix, formerly International Isotopes, manufactures radioisotope products for medical, industrial and research applications. Its Form 10-Q filed on Nov. 16 covers the period ended Sept. 30 and reports in U.S. dollars.
The October credit facility has a 12-month term and bears interest at the prime rate. Borrowing limits depend on eligible accounts receivable and inventory, and the facility is secured by receivables, inventory and equipment.
The credit ceiling is separate from the Sept. 30 cash balance, while restricted funds back a regulatory obligation. Neither should be added to reported cash as though it were an unrestricted balance already available to spend.
Quarterly net loss also differs from cash consumed in operations, so dividing cash by the loss would not establish a reliable runway.
For the third quarter of 2026, gross profit fell to US$1.51 million while the gross margin held at 59 per cent. Operating expenses rose 8 per cent to US$2.30 million in the quarter, partly reflecting professional services, licence costs and medical-device development.
Cobalt Deliveries Move To Early 2027
Radnostix said approximately US$1.2 million in contracted cobalt deliveries had moved from the second half of 2026 to the first quarter of 2027. The contracts await NRC amendments to its registered sealed source devices, according to the release.
"Our Cobalt and Calibration & Reference results were held back by contract timing tied to NRC sealed source amendments and by a global cobalt-57 supply interruption," chief executive Shahe Bagerdjian said in the release.
For the third quarter of 2026, theranostics revenue rose 15 per cent to US$1.71 million, partly offsetting weakness elsewhere. The company also reported that commercial shipments of gadolinium-153 calibration products resumed in November after a global outage.
The proposed disposal of the Fluorine Products assets offers another potential source of liquidity. Under the agreement described in the Nov. 16 release, Radnostix would receive US$9.5 million in cash and US$4 million in restricted shares.
Those assets relate mainly to a depleted uranium deconversion and fluorine extraction plant previously planned for New Mexico. Closing requires NRC approval of the licence transfer and the buyer obtaining ownership or a valid leasehold interest in the site; Radnostix cautioned that the sale might not close.
Read more: Oklo signs Centrus fuel contracts for Ohio Aurora deliveries from 2029
The next delivery target is the deferred cobalt contracts in the first quarter of 2027, subject to the NRC amendments.
Ines Halvorsen






